| Date |
Title |
| Dec 12, 2017 |
Pluristem Granted Manufacturer Authorization and Good Manufacturing Practice (GMP) Certification by Israel’s Ministry of Health, Supporting Pivotal-Stage Studies |
|
| Dec 07, 2017 |
Pluristem to Present Data on PLX-R18 in Treatment of Acute Radiation Syndrome at American Society of Hematology’s Annual Meeting |
|
| Nov 29, 2017 |
Peer-Reviewed Article Published on Pluristem’s PLX-PAD Cells’ Mechanism of Action to Restore Blood Flow in Ischemic Tissue |
|
| Nov 22, 2017 |
Pluristem Granted Key U.S. Patent for Skeletal Muscle Regeneration – a Meaningful Asset Ahead of Upcoming Phase III Femoral Neck Fracture Study |
|
| Nov 14, 2017 |
Pluristem Reports First Quarter Fiscal 2018 Corporate and Financial Highlights |
|
| Nov 06, 2017 |
Pluristem Enters into Agreement with Tel Aviv Sourasky Medical Center to Conduct Phase I/II Trial in Steroid-Refractory Chronic GvHD |
|
| Oct 30, 2017 |
Pluristem announces pricing of public offering of common stock on the Tel Aviv Stock exchange |
|
| Oct 29, 2017 |
Pluristem proposes to launch a public offering of common stock on the Tel Aviv stock exchange after concluding an Israeli institutional investor tender |
|
| Oct 26, 2017 |
Following Approval of Israel’s Ministry of Health, Pluristem Extends its Trial of PLX-R18 to Treat Insufficient Hematopoietic Recovery after Bone Marrow Transplant and Opens Clinical Centers in Israel |
|
| Oct 23, 2017 |
Pluristem Expands its Reach in the Treatment of Impaired Hematopoietic Systems with a European Patent Covering PLX-R18 in Chemotherapy, ARS, Genetic Disorders and Autoimmune Diseases |
|
| Oct 19, 2017 |
FDA Grants Pluristem Orphan Drug Designation for Its PLX-R18 Cell Therapy as Treatment for Acute Radiation Syndrome |
|
| Oct 16, 2017 |
New Published Data Highlights the Potential of Pluristem’s PLX Cells in Improving Cardiac Function in Diabetes |
|
| Oct 02, 2017 |
$7.9 Million Granted to nTRACK Collaborative Project Designed to Study Pluristem’s PLX-PAD Cells |
|
| Sep 26, 2017 |
Pluristem Receives Positive Feedback from FDA and EMA as Company Prepares for Phase III Trial of PLX-PAD to Support Recovery from Hip Fracture |
|
| Sep 18, 2017 |
U.S. FDA Grants Fast Track Designation to Pluristem’s PLX-PAD for the Treatment of Critical Limb Ischemia (CLI) |
|
| Sep 13, 2017 |
Pluristem Strengthens Its Position in Asia, Awarded Two New Patents in Hong Kong for Critical Limb Ischemia and Muscle Regeneration |
|
| Sep 11, 2017 |
Pluristem Reports Fourth Quarter and Fiscal 2017 Corporate and Financial Highlights |
|
| Sep 05, 2017 |
$8.7 Million Awarded to Support Phase III Femoral Neck Fracture Trial by EU Horizon 2020 Program |
|
| Aug 16, 2017 |
U.S. Department of Defense to Conduct Studies of Pluristem’s PLX-R18 in a New ARS Project for Use Before Radiation Exposure |
|
| Aug 09, 2017 |
Israeli Government to Support Pluristem’s Marketing Activity in China; Ministry of Economy Awards Company “Smart Money” Grant |
|
| Jul 26, 2017 |
New Data from ARS Study Shows Significant Hematological Deficiencies Even at Low Radiation Levels; PLX-R18 Supports Hematological Recovery |
|
| Jul 10, 2017 |
Pluristem Advances its Multinational Phase III Critical Limb Ischemia Study, Targeting Initiation at 40 Active Sites by the End of 2017 |
|
| Jun 29, 2017 |
Pluristem to Present New Data from ARS study at Radiology Conference in U.S. |
|
| May 22, 2017 |
Pluristem Provides Shareholder Update on Corporate and Clinical Developments – Third Quarter 2017 |
|
| May 18, 2017 |
Video for Shareholders- Non Human Primates Study Results for Acute Radiation Syndrome. |
|
| May 03, 2017 |
Pluristem Announces Promising Results from Non-Human Primate Pilot Study of PLX-R18 in Acute Radiation Syndrome |
|
| Apr 19, 2017 |
Pluristem Reaches Milestone of 100 Granted Patents, Including Coverage of Leading Indications in Major Markets |
|
| Mar 30, 2017 |
Pluristem and Sosei CVC Advancing Towards Finalizing Joint Venture for the Commercialization of PLX-PAD in Japan |
|
| Mar 29, 2017 |
Pluristem Launches Co-CEO Structure and Appoints New CFO |
|
| Feb 13, 2017 |
Pluristem Reports Second Quarter Fiscal 2017 Highlights & Provides Calendar 2017 Outlook |
|
| Jan 25, 2017 |
Pluristem Announces Closing of Bought Offering and Underwriter’s Exercise in Full of Over-Allotment Option |
|
| Jan 22, 2017 |
Pluristem Increases Previously Announced Bought Deal Offering of Common Stock and Warrants to $15,000,000 |
|
| Jan 19, 2017 |
Pluristem Announces Bought Deal Offering |
|
| Jan 17, 2017 |
Pluristem Receives Clearance from Germany to Initiate its Multinational Phase III Trial in Critical Limb Ischemia Targeting Early Conditional Marketing Approval |
|
| Jan 12, 2017 |
Pluristem Completes Patient Enrollment in a Large Multinational Phase II Trial in Intermittent Claudication |
|
| Jan 10, 2017 |
Pluristem’s Phase III Study of PLX-PAD Cells for the Treatment of Critical Limb Ischemia Cleared by U.S. FDA |
|
